Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Topics
- Definition of DILI
- Types of DILI
- Mechanisms of DILI (1)
- Mechanisms of DILI (2)
- The case of acetominophen intoxication
- Drugs that potentially cause liver injury
- Safety withdrawals 1960-1999
- Signals of DILI in drug development
- Scope of DILI
- Cost of drug development
- Epidemiology of DILI (1)
- Etiology of ALF in the USA
- Tip of the iceberg
- Epidemiology of DILI (2)
- Clinical patterns of DILI
- Image of a normal liver (1)
- Image of a normal liver (2)
- Hepatocellular liver injury (1)
- Hepatocellular liver injury (2)
- Biochemistry of hepatocellular injury
- Cholestatic liver injury
- Biochemistry of cholestatic injury
- What comprises liver injury?
- What comprises liver injury in 2008?
- Adaptation to injury (tolerance)
- Adaptation in DILI
- Toxicity grading in clinical trials
- Jaundice and DILI
- Hepatocellular jaundice
- Bile lakes and apoptotic hepatocytes
- Acute hepatocellular jaundice
- Cholestatic jaundice
- Common "signatures" of DILI
- Susceptibility factors for DILI
- Key elements in diagnosis
- Diagnosis of DILI
- Causality assessment tools in DILI
- Causality assessment
- Management of DILI
- Rumack-Matthew nomogram
- Monitoring in clinical practice
- DILIN
- Summary
- Thank you
Topics Covered
- Definition of drug induced liver injury (DILI)
- Types and mechanisms of DILI
- Safety withdrawals
- Signals of DILI in drug development
- Epidemiology of DILI
- Clinical patterns
- Hepatocellular liver injury
- Cholestatic liver injury
- What comprises liver injury?
- Adaptation to injury
- Toxicity grading in clinical trials
- Jaundice
- Common signatures of DILI
- Susceptibility factors for DILI
- Key elements in diagnosis
- Causality assessment tools
- Management of DILI
- Monitoring in clinical practice
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Navarro, V. (2009, July 30). Drug induced liver injury: a clinical perspective [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/UFJZ3421.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Victor Navarro has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.